Kunal Potnis, MD
Hospital Resident
Research & Publications
Biography
News
Coauthors
Selected Publications
- Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United StatesPotnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.
- Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphomaPotnis K, Huntington S. Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma. Blood Advances 2023, 7: 2573-2574. PMID: 36745098, PMCID: PMC10242627, DOI: 10.1182/bloodadvances.2023009864.
- Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphomaPotnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.
- Artificial Intelligence in Breast Cancer ScreeningPotnis K, Ross J, Aneja S, Gross C, Richman I. Artificial Intelligence in Breast Cancer Screening. JAMA Internal Medicine 2022, 182: 1306-1312. PMID: 36342705, PMCID: PMC10623674, DOI: 10.1001/jamainternmed.2022.4969.
- When competition is not enough: leveraging US policies to curb oral anticancer drug costsPotnis KC, Huntington SF. When competition is not enough: leveraging US policies to curb oral anticancer drug costs. The Lancet Oncology 2022, 23: 836-837. PMID: 35772451, DOI: 10.1016/s1470-2045(22)00297-2.
- Industry Payments and New Breast Cancer Screening Technology UsePotnis KC, Gross CP, Richman IB. Industry Payments and New Breast Cancer Screening Technology Use. Journal Of General Internal Medicine 2020, 36: 1440-1442. PMID: 32468434, DOI: 10.1007/s11606-020-05771-9.
- Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.Potnis KC, Flueckinger LB, Ha CI, Upadia J, Frush DP, Kishnani PS. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy. Mol Genet Metab 2019, 126: 157-161. PMID: 30448006, DOI: 10.1016/j.ymgme.2018.11.004.
- Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum.Potnis KC, Flueckinger LB, DeArmey SM, Alcalay RN, Cooney JW, Kishnani PS. Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum. Mol Genet Metab Rep 2018, 17: 69-72. PMID: 30364808, DOI: 10.1016/j.ymgmr.2018.10.001.